What Is Wegovy (Semaglutide 2.4mg)?
Wegovy is a once-weekly injectable medication containing semaglutide at a higher concentration than Ozempic, specifically developed and FDA-approved for chronic weight management in adults and adolescents with obesity. It became one of the most talked-about pharmaceuticals in modern medicine — not because it was a new molecule, but because it worked at a level of efficacy that had previously required bariatric surgery to achieve. Understanding Wegovy means understanding how a drug originally developed for type 2 diabetes transformed the field of obesity medicine.
Wegovy vs. Ozempic: Same Molecule, Different Purpose
Both Wegovy and Ozempic contain semaglutide, manufactured by Novo Nordisk. The critical differences are in the maximum approved dose and the FDA-approved indication:
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Maximum approved dose | 2.4 mg/week | 2 mg/week |
| Primary FDA indication | Chronic weight management (obesity/overweight + comorbidity) | Type 2 diabetes glycemic control + CV risk reduction |
| Approved populations | Adults; adolescents ≥12 years (obesity) | Adults with T2D |
Because they contain the same molecule, Ozempic was widely prescribed off-label for weight loss before and during Wegovy shortages — a practice that contributed to significant supply disruptions for people with type 2 diabetes who depended on Ozempic for glycemic management.
FDA-Approved Indications for Wegovy
Wegovy is approved for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in:
- Adults with a BMI of 30 kg/m² or greater (obesity)
- Adults with a BMI of 27 kg/m² or greater (overweight) who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
- Adolescents aged 12 years and older with obesity (BMI ≥95th percentile for age and sex)
- Adults with established cardiovascular disease and obesity or overweight (for reduction of cardiovascular events — added after SELECT trial results)
The STEP Trials: What the Evidence Shows
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program was the pivotal evidence base for Wegovy's approval. STEP 1 — the landmark trial — enrolled 1,961 adults with obesity or overweight without type 2 diabetes. After 68 weeks at the 2.4 mg dose, participants lost an average of 14.9% of their body weight compared to 2.4% in the placebo group. Nearly one-third of participants lost more than 20% of body weight. STEP 3 combined weekly semaglutide with an intensive behavioral intervention and demonstrated even greater weight loss. STEP 4 showed that discontinuing semaglutide led to weight regain, underscoring that this is a chronic treatment for a chronic condition.
The SELECT Trial: A Cardiovascular Drug, Not Just a Weight Loss Drug
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial enrolled 17,604 adults with established cardiovascular disease who were overweight or obese but did not have type 2 diabetes. This was a critical distinction — it demonstrated cardiovascular benefit in a population not traditionally targeted with diabetes medications. After a mean follow-up of approximately 3.3 years, Wegovy reduced the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% compared to placebo. This result led to a new FDA approval for cardiovascular risk reduction in adults with established CVD and obesity or overweight.
Side Effects
Gastrointestinal effects
Nausea, vomiting, diarrhea, and constipation are the most common side effects, particularly during dose escalation. The standard titration schedule increases the dose gradually over 16–20 weeks to minimize GI intolerance. Most patients experience improvement after the initial adjustment period, though some continue to have intermittent GI symptoms throughout treatment.
Gastroparesis-like effects
The significant slowing of gastric emptying caused by semaglutide can progress to a clinically significant degree in some patients, producing persistent nausea, early satiety, and vomiting of undigested food. This has important implications for patients undergoing surgery or procedures requiring anesthesia — anesthesiologists now commonly ask about GLP-1 agonist use and may require extended fasting periods or pre-procedure discontinuation.
BLACK BOX WARNING — THYROID C-CELL TUMORS: Semaglutide caused thyroid C-cell tumors in rodent studies at clinically relevant exposures. Human relevance is unknown. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Patients should report any symptoms of thyroid tumors: lump or swelling in the neck, difficulty swallowing, hoarseness, shortness of breath.
PANCREATITIS: Cases of acute pancreatitis have been reported with GLP-1 agonists. Discontinue Wegovy immediately if pancreatitis is suspected. Do not restart if confirmed.
Compounded Semaglutide: A Significant Safety Concern
During periods of Wegovy and Ozempic shortage, the FDA permitted compounding pharmacies to produce semaglutide under enforcement discretion. These compounded products used semaglutide salts rather than the base compound used in approved products and were not reviewed for safety, efficacy, or manufacturing quality by the FDA. Reports of serious adverse events — including severe hypoglycemia from dosing errors, contamination concerns, and products of unknown purity — emerged. The FDA wound down this enforcement discretion in 2025 as the shortage resolved. Patients should use only FDA-approved semaglutide products from their pharmacy.
Cost and Insurance Coverage
Wegovy's list price has been in the range of $1,300–$1,700 per month. Insurance coverage varies dramatically. Medicare Part D historically excluded coverage for anti-obesity medications, though policy has been evolving. Many commercial insurers cover Wegovy for patients meeting clinical criteria, often requiring prior authorization and documentation of other weight management attempts. Novo Nordisk offers a savings card program for commercially insured patients. Patients without coverage face substantial out-of-pocket costs that limit long-term access.
Want to compare Wegovy to Mounjaro/Zepbound or check for drug interactions?
Compare MedicationsFrequently Asked Questions
Wegovy and Ozempic both contain semaglutide, but they are different FDA-approved products with different indications and maximum doses. Wegovy's highest approved dose (2.4 mg/week) is higher than Ozempic's (2 mg/week) and is approved for chronic weight management. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction in people with T2D. Using one interchangeably with the other is not appropriate without medical guidance.
In the STEP 1 clinical trial, participants lost an average of approximately 15% of their body weight over 68 weeks, compared to about 2.4% with placebo — a net treatment effect of around 12.5%. Individual results vary considerably. Some people achieve more than 20% weight loss; others lose less. Factors that influence response include adherence to the medication schedule, dietary changes, physical activity, and individual metabolic and genetic factors. Weight regain typically occurs if the medication is stopped.
Insurance coverage for Wegovy is inconsistent. Many commercial health plans do cover it, particularly for patients with a BMI meeting criteria and at least one weight-related comorbidity, often requiring prior authorization. Medicare Part D historically excluded coverage for anti-obesity medications, though this has been a topic of active policy discussion. Medicaid coverage varies by state. Patients should contact their insurer directly and ask their prescriber to assist with prior authorization documentation. Novo Nordisk's patient assistance programs may help those with coverage gaps.